Home>Topics>>Ariad: Shares Overvalued On Fundamentals
Ariad: Shares Overvalued On Fundamentals
Healthcare Sector and Stocks Analysis from Seeking Alpha
Tue, 5 Feb 2013
By Poonam A. Arora : Ariad Pharmaceuticals ( ARIA ) is a biotechnology company that discovers, develops, and commercializes treatments for cancer. Last December, its lead drug Ponatinib was approved by the FDA for managing chronic myeloid leukemia ( CML ) and Philadelphia chromosome-positive acute ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.